Prevention and Screening
Prevention and screening is the area of family medicine concerned with reducing the burden of disease before it produces symptoms, by identifying and modifying risk factors and by detecting disease early in apparently healthy people. It organises the preventive tasks that recur across a primary-care population — counselling, immunisation, risk assessment, and screening tests — and the evidence and judgement needed to apply them appropriately.
Definition
Prevention and screening comprises the clinical activities aimed at averting disease (prevention) and at detecting disease or its precursors before symptoms appear (screening), structured by the population's risk profile and the strength of supporting evidence.
Scope
The area covers the conceptual levels of prevention (primary, secondary, tertiary), the principles that make a screening programme worthwhile, and the recurring preventive priorities of generalist practice. Its topics here are cardiovascular disease prevention, cancer screening and prevention, smoking cessation, and obesity and weight management. It treats prevention as a reference and educational subject within family medicine, summarising how preventive evidence is generated and appraised rather than issuing individual clinical instructions.
Sub-topics
Core questions
- When does detecting a disease earlier actually improve outcomes rather than merely lengthening the time a person is labelled as ill?
- Which preventive interventions have benefits that outweigh their harms and costs across a whole primary-care population?
- How should individual risk be estimated and communicated so that prevention is offered to those most likely to benefit?
Key concepts
- Primary, secondary, and tertiary prevention
- Screening versus diagnostic testing
- Wilson and Jungner screening principles
- Lead-time and length-time bias
- Overdiagnosis and overtreatment
- Absolute versus relative risk reduction
- Number needed to screen or treat
- Risk stratification and shared decision-making
Mechanisms
Prevention works along a continuum. Primary prevention removes or reduces a cause before disease begins — for example through tobacco cessation or cardiovascular risk-factor control. Secondary prevention detects disease in a presymptomatic stage where treatment is more effective, which is the logic of screening programmes such as colorectal and cervical cancer screening. Tertiary prevention limits the impact of established disease. Screening adds a test to an asymptomatic population, so its value depends not only on test accuracy but on whether earlier detection changes the disease course; apparent benefits can be inflated by lead-time bias (detecting disease earlier without changing the time of death) and length-time bias (preferentially catching slow-growing disease), and screening can cause harm through overdiagnosis of disease that would never have become clinically important.
Clinical relevance
Preventive and screening decisions are among the most frequent encounters in family medicine and shape population health at scale. Bodies such as the US Preventive Services Task Force synthesise the evidence into graded recommendations that clinicians and patients weigh together. This entry describes the reasoning and evidence behind such recommendations for educational reference; it is not a protocol for individual screening or treatment decisions, which depend on personal risk, values, and current local guidance.
Epidemiology
Much of the modern chronic-disease burden — cardiovascular disease, common cancers, and conditions driven by tobacco use and obesity — is partly preventable, which is why prevention occupies a central place in primary care. Global burden-of-disease analyses consistently rank tobacco, high blood pressure, and high body-mass index among the leading modifiable contributors to death and disability, underscoring the population relevance of the topics gathered in this area.
Evidence & guidelines
Preventive practice in primary care is strongly guideline-driven. The US Preventive Services Task Force issues evidence-graded recommendations on screening and counselling (for example statins for primary cardiovascular prevention, colorectal cancer screening, and tobacco-cessation interventions), and specialty societies such as the ACC/AHA provide complementary prevention guidelines. These documents are periodically updated as evidence accrues, so any specific recommendation should be checked against its current version.
History
Systematic thinking about screening was crystallised by Wilson and Jungner's 1968 World Health Organization monograph, which set out the principles a screening programme should satisfy. Over the following decades preventive medicine moved from ad hoc check-ups toward evidence-graded, population-oriented recommendations, formalised in many countries through task forces that appraise benefits and harms before endorsing a preventive service.
Debates
- How much screening is too much?
- Expanding screening can detect disease that would never have caused harm (overdiagnosis), leading to overtreatment; balancing earlier detection against this harm is a recurring tension across cancer and cardiovascular screening.
Key figures
- James Maxwell Glover Wilson
- Gunnar Jungner
Related topics
Seminal works
- uspstf-statin-2022
- uspstf-colorectal-2021
- uspstf-tobacco-2021
Frequently asked questions
- What is the difference between prevention and screening?
- Prevention aims to stop disease from occurring or progressing, while screening is one tool of prevention that tests apparently healthy people to detect disease, or its precursors, early enough to improve outcomes.
- Why isn't earlier detection always better?
- Detecting disease earlier only helps if it changes the disease course. Lead-time and length-time bias can make screening look beneficial when it is not, and screening can harm people by diagnosing and treating disease that would never have caused problems.